Clinical Laserthermia Systems AB Class B (CLS.B) AI Stock Analysis

• Market Cap: kr233.57M
• Dividend Yield: N/A
• Average Volume (3M): 267.18K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.63
• Revenue Growth: 57.14%
• EPS Growth: 81.07%
• Country: SE
• Employees: 17
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.25
• Shares Outstanding: 25,663,593
• 10 Day Avg. Volume: 215,321
• 30 Day Avg. Volume: 267,180
• PEG Ratio: 0.01
• Price to Book (P/B): 0.59
• Price to Sales (P/S): 2.15
• P/FCF Ratio: -0.68
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): kr37.10M

• Rating: 49 Neutral
• Price Target: kr8.50 ▲(9.25% Upside)

The overall stock score of 49 reflects significant financial challenges, including negative profitability and cash flow issues, despite strong revenue growth. Technical indicators show mixed momentum, and the valuation is unattractive due to ongoing losses. The absence of earnings call data and corporate events limits additional insights.

Clinical Laserthermia Systems AB Class B Business Overview & Revenue Model

Company Description

Clinical Laserthermia Systems AB Class B (CLS.B) is a Swedish medical technology company specializing in the development of innovative laser-based therapies for the treatment of cancer and other serious diseases. The company's core product offerings include advanced laser systems designed to provide precise and effective thermal therapy, enhancing treatment outcomes while minimizing damage to surrounding healthy tissues. CLS.B operates primarily within the healthcare sector, focusing on both clinical applications and partnerships with hospitals and medical professionals to integrate their laser technologies into standard treatment protocols.

How the Company Makes Money

CLS.B generates revenue through the sale of its laser therapy systems and related consumables to hospitals, clinics, and healthcare providers. The company also earns income through service agreements for maintenance and support of its equipment, as well as training programs for healthcare professionals to ensure effective use of their technologies. Additionally, CLS.B may engage in strategic partnerships with medical institutions and research organizations to conduct clinical trials and studies that validate the effectiveness of their products, potentially leading to increased sales and market penetration. These partnerships can also provide access to funding and resources, contributing to the company's overall financial performance.

Clinical Laserthermia Systems AB Class B Financial Statement Overview

Summary

Clinical Laserthermia Systems AB Class B exhibits strong revenue growth and a healthy gross profit margin, but faces significant profitability challenges with negative net income and cash flow issues. The balance sheet is robust with low leverage, but the company struggles to generate returns on equity.

Income Statement

The company shows a strong revenue growth rate of 18.57% in the TTM, indicating positive momentum. However, the net profit margin is significantly negative at -180.95%, and both EBIT and EBITDA margins are deeply negative, reflecting ongoing operational challenges and high costs relative to revenue. The gross profit margin is healthy at 73.99%, suggesting effective cost management at the gross level.

Balance Sheet

The balance sheet is stable with a very low debt-to-equity ratio of 0.0033, indicating minimal leverage and financial risk. However, the return on equity is negative at -63.84%, highlighting inefficiencies in generating returns for shareholders. The equity ratio is strong, suggesting a solid capital structure.

Cash Flow

The company has a negative free cash flow growth rate of -7.80% in the TTM, indicating declining cash generation. The operating cash flow to net income ratio is negative, reflecting cash flow challenges. However, the free cash flow to net income ratio is positive at 1.18, suggesting some ability to cover net losses with free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	23.88M	18.78M	8.27M	6.27M	2.25M	1.33M
Gross Profit	17.67M	10.42M	3.00M	-2.79M	-3.63M	876.00K
EBITDA	-40.11M	-44.76M	-68.41M	-57.84M	-57.05M	-51.61M
Net Income	-43.21M	-47.62M	-79.79M	-70.66M	-63.62M	-57.94M
Balance Sheet
Total Assets	72.10M	78.56M	57.73M	49.51M	66.74M	44.40M
Cash, Cash Equivalents and Short-Term Investments	16.20M	22.51M	15.33M	10.59M	31.17M	11.87M
Total Debt	224.00K	224.00K	454.00K	30.68M	273.50K	673.50K
Total Liabilities	7.67M	12.88M	14.20M	41.64M	45.55M	30.47M
Stockholders Equity	67.23M	68.72M	45.77M	9.22M	21.79M	13.93M
Cash Flow
Free Cash Flow	-50.71M	-58.92M	-71.95M	-71.25M	-66.73M	-55.76M
Operating Cash Flow	-42.88M	-56.45M	-66.45M	-70.69M	-66.17M	-55.41M
Investing Cash Flow	-5.95M	-7.47M	-5.50M	-886.00K	-408.00K	-508.00K
Financing Cash Flow	53.06M	71.10M	76.69M	61.84M	85.88M	62.02M

Clinical Laserthermia Systems AB Class B Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.78
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CLS.B, the sentiment is Positive. The current price of 7.78 is below the 20-day moving average (MA) of 8.01, below the 50-day MA of 8.69, and above the 200-day MA of 5.00, indicating a bullish trend. The MACD of 0.13 indicates Negative momentum. The RSI at 55.63 is Neutral, neither overbought nor oversold. The STOCH value of 68.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:CLS.B.

Clinical Laserthermia Systems AB Class B Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CLS.B	49 Neutral	kr233.57M	―	-78.89%	―	57.14%	81.07%
LXB	46 Neutral	kr89.80M	―	-60.20%	―	163.12%	30.50%
NOSA	44 Neutral	kr186.92M	-19.94	―	―	17.24%	35.77%
SPEC	39 Underperform	kr88.69M	―	-19.36%	―	―	-61.38%
HEART	34 Underperform	kr74.48M	―	―	―	―	―